@FiercePharma: Claris injectables unit seen as M&A target for Teva, Pfizer, now that Mylan has Agila Specialties. More | Follow @FiercePharma
@EricPFierce: FDA acts quickly to assess potential cancer risks of type 2 diabetes drugs, Merck's Januvia, BMS' Byetta. Story | Follow @EricPFierce
> Teva Pharmaceutical ($TEVA) will pay $2.25 million to settle alleged environmental violations over a plant in Mexico, MO. Report
> Kallam Anji Reddy, 73, founder and chairman of Dr Reddy's Laboratories, died Friday in India after brief illness. Item
> Some members of Congress are displeased with an FDA response as to how long it could take to put greater restrictions on prescription painkillers like Vicodin. Story
> The FDA has officially withdrawn Impax Laboratories' bupropion hydrochloride which the agency asked last fall to be taken off the market over concerns of its bioequivalence. Report
> The FDA has given Par Pharmaceutical the go-ahead to make a generic version of Jazz Pharmaceuticals' Luvox CR. Item
@FierceMedDev: Intuitive slides as doc group slams robotic surgery 'hype. More | Follow @FierceMedDev
@MarkHFierce: A brain Dx would measure tumor DNA to gauge how advanced breast cancer patients are responding to drugs. Article | Follow @MarkHFierce
@DamianFierce: Illumina has to fork over $96 million in a patent suit over sequencing. Story | Follow @DamianFierce
> Sorin banks on up to 30% profit growth in 2013. More
> Study: Johns Hopkins brain stent saves patients from blindness. Article
Biotech News
@FierceBiotech: Novartis grabs FDA's coveted 'breakthrough' status for lung cancer drug. More | Follow @FierceBiotech
@JohnCFierce: Tillman Gerngross (Adimab) has a new biotech startup, Avitide. A service company: More | Follow @JohnCFierce
@RyanMFierce: Merck hit with delay on FDA review of top drug prospect. Article | Follow @RyanMFierce
> Biotech startup Avitide attracts venture funding from familiar VC crowd. More
> Biotech Chimerix reveals ex-Pharmasset recruit after unveiling $85M IPO plan. Report
And Finally... In a long but not very insightful interview, former Novartis ($NVS) Chairman Daniel Vasella talks about his fight over an abandoned $76 million payout and his decision to move to the U.S. Story